首页>
外国专利>
Biomarketer for the measurement of the effect of drugs on enteropathic disease
Biomarketer for the measurement of the effect of drugs on enteropathic disease
展开▼
机译:生物营销师,用于衡量药物对肠病的影响
展开▼
页面导航
摘要
著录项
相似文献
摘要
The response of a patient with an enteropathic disease to therapy, particularly a candidate therapy in a clinical trial setting, is assessed by detecting the ability of the patient to metabolize an orally administered CYP3A substrate. The CYP3A metabolism may be monitored in a variety of ways. Conveniently, the appearance of a metabolite of the CYP3A substrate is detected in a patient sample over a period of time following oral administration, e.g. in urine, plasma, breath, saliva, etc. The CYP3A substrate is optionally labeled, e.g. with an isotopic, fluorescent, etc. label.
展开▼